# Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

> **NCT00380224** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 120 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** bifeprunox, olanzapine

## Key facts

- **NCT ID:** NCT00380224
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2007-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380224, "Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00380224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*